CytomX Therapeutics, Inc. — FY 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing was signed March 1, 2022. CytomX is a clinical-stage oncology biotechnology company; it had no products approved for sale and generated no product-sales revenue. Its revenue came from collaboration agreements and related research services, milestones and license payments.
Financial performance and position
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | $69.6 million | $100.4 million |
| Research and development expense | $114.2 million | $112.9 million |
| General and administrative expense | $39.2 million | $36.0 million |
| Operating loss | $83.8 million | $48.6 million |
| Net loss | $83.6 million | $32.9 million |
| Net loss per share, basic and diluted | $1.30 | $0.71 |
| Cash used in operating activities | $119.0 million | Cash provided: $5.3 million |
| Cash, cash equivalents and investments at year-end | $305.2 million | $316.1 million |
FY 2021 operating and net loss margins were approximately 120% of revenue; gross margin is not presented as a meaningful measure in the filing. The company reported no debt balance in the provided financial statements. It had $89.4 million in stockholders’ equity and $250.0 million in total liabilities, including $21.7 million in operating lease liabilities. Current assets were $310.3 million and current liabilities $106.3 million.
Cash from financing was $110.2 million, principally from the January–February 2021 public offering, which raised $107.7 million net. Year-end cash and cash equivalents were $205.5 million, with $99.7 million in short-term investments. Deferred revenue totaled $194.9 million, reflecting collaboration consideration to be recognized as CytomX performs its obligations.
Material changes versus FY 2020
- Revenue declined $30.8 million, mainly because FY 2020 included recognition of part of AbbVie’s $40 million CX-2029 dose-escalation milestone and a $10 million Bristol Myers Squibb milestone. Higher Astellas revenue partly offset the decline.
- Net loss rose $50.7 million. The comparison is affected by a $13.9 million income-tax benefit in 2020 from CARES Act net operating loss carrybacks; there was no income-tax benefit in 2021.
- Operating cash flow shifted from $5.3 million provided to $119.0 million used. The 2021 cash use included a $66.2 million decrease in deferred revenue as previously received collaboration payments were recognized.
- R&D expense increased modestly by $1.3 million, with higher CX-2029 and CX-2009 spending largely offset by lower pacmilimab and other program costs. G&A expense increased $3.1 million, primarily from personnel and recruiting costs.
- Common shares outstanding rose from 48.3 million to 65.4 million, mainly due to the 16.4 million-share offering.
Business, outlook and risks
CytomX’s Probody platform is designed to conditionally activate biologic therapies in the tumor environment. Its clinical programs included wholly owned praluzatamab ravtansine (CX-2009) and pacmilimab (CX-072), and partnered CX-2029, BMS-986249, BMS-986288 and CX-904. CX-904’s IND was allowed to proceed by the FDA in January 2022; the company expected to dose the first patient in the first half of 2022. CX-2043 remained preclinical.
Management stated that existing capital resources were expected to fund planned operations for at least 12 months from issuance of the financial statements. CytomX expects significant losses and R&D spending to continue, does not expect near-term product-sales revenue, and said it will need additional funding in the future. No specific earnings or revenue guidance was provided.
- Clinical outlook: Initial CX-2009 Phase 2 data for monotherapy breast-cancer arms were expected in the second half of 2022. Additional CX-2029 data updates were expected in 2022. These were expectations, not guaranteed outcomes.
- Clinical and safety risks: CX-2029 Phase 2 data showed substantial treatment-related anemia, including Grade 3 anemia in 67.3% of the reported safety population; the cause was under investigation. CX-2009 also had payload-related toxicities, including ocular effects. Early or preliminary results may change as data mature.
- Execution and funding risks: COVID-19 had delayed site activation and enrollment, including CX-2009. The company depends on collaborators and third-party clinical and manufacturing providers, many without long-term contracts or alternatives; scale-up and product supply remain risks.
- Collaboration dependence: The majority of revenue came from a small number of partners, and future revenue depends on research progress, milestones and partner decisions. Future milestones and royalties are uncertain.
- Legal contingency: Vytacera Bio’s patent-infringement lawsuit concerning basic-research uses of the Probody platform remained pending, with case deadlines stayed pending claim-construction disputes. CytomX said it believed the claim was without merit, but recorded no accrual and could not estimate a loss range.
- Other disclosures: Ernst & Young issued an unqualified opinion on the financial statements and internal controls; management and the auditor concluded internal control over financial reporting was effective at year-end.
Investor facts to verify
- Whether the stated minimum 12-month cash runway remains adequate given operating cash use, trial enrollment and manufacturing costs, and the company’s need for future financing.
- Final, sufficiently mature efficacy and safety data for CX-2009 and CX-2029, especially CX-2029 anemia rates and the clinical significance of reported response data.
- Progress, enrollment and timing for CX-904 and other clinical programs, including any changes to management’s stated 2022 expectations.
- Partner funding, target-selection and development decisions, and the timing and conditions for potential milestone payments.
- Developments in the Vytacera litigation, potential exposure and any change to the company’s no-accrual position.
- Potential dilution from future equity financing and the effect of collaboration revenue recognition on reported revenue and operating cash flow.